4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies

San Francisco, CA US
October 5, 2024 to October 6, 2024

The 4th Binaytara Precision Oncology Summit is a 2-day CME-accredited conference that offers an unparalleled opportunity for oncology professionals to delve into the latest advancements, innovations, and practices in precision oncology. The theme for this year's summit, "Current Standards and Emerging Therapies," highlights the conference's commitment to providing a comprehensive overview of the field, including in-depth discussions on the latest developments in precision oncology, alongside a thorough examination of established treatment protocols. Focus on actionable mutations ensures that the presented information translates directly into improved patient care.

The summit features didactics, panel discussions, interactive case studies, and scientific abstract presentations. 

This conference will augment healthcare providers' foundation of knowledge and clinical competence in several areas, including:

  • Integrating different platforms available for testing actionable molecular alterations to identify targeted therapy options.
  • Current and evolving paradigms in precision oncology approach for management of common malignancies.
  • Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies.

Target Audience

  • Hematologists/Oncologists
  • Oncology Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Physician Assistants
  • Oncology Fellows/Residents
  • Oncology Nurses
  • Researchers and others involved in the care of cancer patients

Organizing Committee 

Program Director:

Dr. Binay Shah - Binaytara Foundation

Organizing Committee:

Dr. Mark Pegram - Stanford University

Dr. Siddhartha Yadav - Mayo Clinic

Abstract Committee Chairs

Dr. Jonathan Wesley Riess - UC Davis

Dr. Marianne E. Dubard-Gault - Swedish Health Services

Abstract Committee

Dr. Mridula Krishnan - University of Nebraska Medical Center

Learning Objectives

Upon successful completion of this educational activity on precision oncology, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
  • Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies.
  • Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in a clinical investigation for cancer patients.
Course summary
Available credit: 
  • 11.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.50 Contact Hours.
Course opens: 
04/02/2024
Course expires: 
12/31/2024
Event starts: 
10/05/2024 - 8:00am PDT
Event ends: 
10/06/2024 - 3:30pm PDT
Cost:
$350.00

DAY 1 - OCTOBER 5th, 2024

 

07:00 AM – 07:45 AM  Registration and Exhibits


07:45 AM – 07:50 AM  Welcome

07:50 AM – 08:00 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities


08:00 AM – 09:00 AM  Session 1: Beyond NGS: Tools in Precision Oncology

Session Chair: Christopher T. Chen, MD

08:00 AM – 08:15 AM  WGS, WES, and Mutational Signatures for identification of complex genomic alterations driving cancer development and progression - Hanlee P. Ji, MD

08:15 AM – 08:30 AM  Potential clinical application(s) of transcriptomics and proteomics

08:30 AM – 08:45 AM  CTCs and ctDNA to aid therapeutic decisions and surveillance

08:45 AM – 09:00 AM  Discussion


09:00 AM – 10:00 AM  Session 2: DNA-repair deficiencies and genomic instability

Session Chair: James M. Ford, MD, FASCO

09:00 AM – 09:15 AM  Biomarkers of DNA-repair deficiencies, HRD, and genomic instability - Joshua Gruber, MD, PhD

09:15 AM – 09:30 AM  Current treatment landscape for HR deficient and genomically unstable tumors

09:30 AM – 09:45 AM  Next generation of DNA-repair deficiency targeted treatments

09:45 AM – 10:00 AM  Discussion


 10:00 AM – 10:30 AM  Break and Exhibits


10:30 AM – 11:45 AM  Session 3: Cancer immunotherapy

Session Chair: Diwakar Davar, MD

10:30 AM – 10:45 AM  Cancer vaccines

10:45 AM – 11:00 AM  Innate immune signaling pathways: How to turn ‘cold’ tumors into ‘hot’ ones?

11:00 AM – 11:15 AM  Predicting response/resistance to immune checkpoint inhibitors - Isaac Chan, MD, PhD

11:15 AM – 11:30 AM  Engineering immune cells to treat cancer (CAR-Ts and beyond) - Bryan Choi, MD, PhD

11:30 AM – 11:45 AM  Discussion


11:45 AM – 01:00 PM  Lunch and Exhibits


01:00 PM – 01:45 PM  Session 4: Keynote

01:00 PM – 01:30 PM  Keynote Lecture

01:30 PM – 01:45 PM  Discussion


01:45 PM – 02:45 PM  Session 5: RAS/RAF/MAPK and PI3kinase/AKT/mTOR Signalling

Session Chair: Shailender Bhatia, MD

01:45 PM – 02:00 PM  Therapeutic opportunities leveraging aberrant RAS/RAF/MAPK signaling

02:00 PM – 02:15 PM  Therapeutic opportunities leveraging aberrant PI3 kinase/AKT/mTOR signaling - Neil M. Iyengar, MD

02:15 PM – 02:30 PM  Resistance mechanisms and challenges to targeting RAS/RAF/MAPK and PI3 kinase/AKT/mTOR pathways - Roger S. Lo, MD, PhD

02:30 PM – 02:45 PM  Discussion


02:45 PM – 04:00 PM  Session 6: Targeting receptor tyrosine kinases

Session Chair: Jonathan Wesley Riess, MD, MS

02:45 PM – 03:00 PM  Targeting receptor tyrosine kinases in cancer across tumor types

03:00 PM – 03:15 PM  A primer on tyrosine kinase inhibitors and implications for management of EGFR, ALK, ROS1, MET and RET altered tumors

03:15 PM – 03:30 PM  HER2 signaling in breast and other cancers, and implications for treatment - Mark Pegram, MD

03:30 PM – 03:45 PM  Overcoming challenges in targeting receptor tyrosine kinases and resistance mechanisms - Xiuning Le, MD, PhD

03:45 PM – 04:00 PM  Discussion


04:00 PM – 06:00 PM  Session 7: Oral abstracts with networking

Session Chairs: Jonathan Wesley Riess, MD, MS and Marianne E. Dubard-Gault, MD, MS


 

DAY 2 - OCTOBER 6th, 2024

 

07:00 AM – 08:30 AM  Session 8: Poster Abstracts and Breakfast

Session Chairs: Jonathan Wesley Riess, MD, MS and Marianne E. Dubard-Gault, MD, MS


08:30 AM – 09:30 AM  Session 9: Hormone Receptor Signaling

Session Chair:

08:30 AM – 08:45 AM  Advances in estrogen receptor signaling and biology

08:45 AM – 09:00 AM  Therapeutic options for ESR1-mutant breast cancers - Aditya Bardia, MD, MPH, FASCO

09:00 AM – 09:15 AM  Treatment strategies targeting the androgen receptor - Evan Y. Yu, MD

09:15 AM – 09:30 AM  Discussion


09:30 AM – 10:45 AM  Session 10: Molecular tumor board

Session Chair: Siddhartha Yadav, MBBS, MD

09:30 AM – 09:45 AM  Classical EGFR mutation positive lung cancer; management over multiple lines of therapy - Deepti Behl, MD

09:45 AM – 10:00 AM  Case 2 - Sant P. Chawla, MD

10:00 AM – 10:15 AM  Case 3

10:15 AM – 10:30 AM  Case 4

10:30 AM – 10:45 AM  Case 5


10:45 AM – 11:00 AM  Break and Exhibits


11:00 AM – 12:00 PM  Session 11: Cancer Interception and Prevention

Session Chair:

11:00 AM – 11:15 AM  Multi-cancer early detection tests – clinical utility and pitfalls - Margaret Tempero, MD

11:15 AM – 11:30 AM  Personalized vaccines for primary or secondary cancer prevention

11:30 AM – 11:45 AM  Precision in cancer risk prediction incorporating genetic, hormonal, and environmental risk factors: Implications for cancer prevention - Fergus J. Couch, PhD

11:45 AM – 12:00 PM  Discussion


12:00 PM – 01:00 PM  Lunch and Exhibits


01:00 PM – 02:00 PM  Session 12: Precision Oncology Drug Development (Part 1)

Session Chair: Shivaani Kummar, MD, FACP

01:00 PM – 01:05 PM  Precision oncology drug development - Shivaani Kummar, MD, FACP

01:05 PM – 01:20 PM  Identifying predictive markers of response and resistance in cancer therapeutics

01:20 PM – 01:35 PM  Role of AI in oncology drug development

01:35 PM – 01:50 PM  How to design precision clinical trials for the rare targets - Ying Lu, PhD

01:50 PM – 02:00 PM  Discussion


02:00 PM – 03:00 PM  Session 13: Precision Oncology Drug Development (Part 2)

Session Chair: Pamela Munster, MD

02:00 PM – 02:15 PM  Antibody-drug conjugates: opportunities and challenges

02:15 PM – 02:30 PM  Monoclonal and Bispecific antibodies: where do we stand now?

02:30 PM – 02:45 PM  Small molecules for precision oncology: opportunities and challenges

02:45 PM – 03:00 PM  Gene-based therapy – is the future here?

03:00 PM – 03:15 PM  Discussion


03:15 PM – 03:30 PM  Closing remarks

Hyatt Regency San Francisco Downtown Soma
50 3rd St
San Francisco, CA 94103
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Session Chair(s)

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Amphivena;.
has a financial relationship (Grant Or Contract) with Exicure;.
has a financial relationship (Grant Or Contract) with Nektar Therapeutics;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Grant Or Contract) with Agenus;.
has a financial relationship (Grant Or Contract) with EMD Serono;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Grant Or Contract) with 4SC;.
has a financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);.
has a financial relationship (Grant Or Contract) with Kuni Foundation;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Trisalus Life Sciences;.

James Ford, MD, FASCO

has no relevant financial relationships to disclose at this time.

Jonathan Riess, MD, MS

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Biodesix;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Professional Services) with Novartis;.
Speaker/Topic Presenter(s)

Mark Pegram, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Gilead;.
Case Presenter(s)

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AZ;.
has a financial relationship (Professional Services) with janssen;.
Planning committee(s)

Mark Pegram, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Gilead;.

Available Credit

  • 11.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.